Hardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020

We are delighted to announce that Open Orphan will be presenting at our next Investor Forum on Thursday 9th July. The Investor Forum connects investors with companies looking for capital. Each company will present for 10-15 minutes, followed by an opportunity for Q&A.

Open Orphan (ORPH) is a publicly traded company on the London AIM and Euronext Growth stock exchanges. The company was founded in 2017 with the aim of becoming a leading specialist CRO pharmaceutical services business. It has a focus on rare disease/orphan drugs, and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. Open Orphan is comprised of two commercial specialist CRO services businesses, hVIVO and Venn Life Sciences; and has offices in London, Dublin, Paris and the Netherlands. The company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. It also provides digital data platforms to support companies in research & development and commercialisation.

https://www.hardmanandco.com/july-2020-virtual-investor-forum/

If you are interested in attending the virtual forum, you can register your interest by clicking on the above link.

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.